BioSpace News Archive

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical will be presenting at the upcoming Emerging Growth Conference to be held on August 18, 2021.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the pivotal Phase 3 ReSTORE trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.

Zenith Capital Corp., a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces a publication in the high-impact Nature Publishing Group journal of Cancer Gene Therapy, titled: “Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.”

Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine, today announced the publication of data from the double-blind, randomized MODERATO II study in the Journal of the American Heart Association (JAHA).

Reflect Scientific, Inc., a provider of diverse products and services for biotechnology, pharmaceutical, and transportation industries, announced financial results for the second quarter of 2021.

I-Mab today announced it will provide business and corporate updates and report financial results for the six months ended June 30, 2021, before the market opens on Tuesday, August 31, 2021.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced the dosing of the first patient in a Phase 3 study of zandelisib known as COASTAL.

Karius has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.

Immix Biopharma, Inc. today announced that Galit Lahav, PhD, Novartis Professor of Systems Biology and Department Chair, Systems Biology at Harvard Medical School has joined its Scientific Advisory Board.

A limited choice of commercial drugs composed of corticosteroid treatments, immunosuppresives and biologics is characteristic of the global uveitis drugs market.